2026-08-06T13:44:10-04:00 2025-12-31 PwC US Tax LLP 655 NEW YORK AVENUE NW SUITE 1100 WASHINGTON DC 20001 990 2025-01-01 473355381 PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY % SARA COBLIN PARK 4159304386 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 KAREN E KNUDSEN COSTELLO CEO 4159304386 2026-08-04 true TRAVIS PATTON P00369623 6464713000 2026-08-03 2025 2025-03-06 01:10:19Z SEAN PARKER 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 180131815 false X WWW.PARKERICI.ORG X 2015 CA SEE SCHEDULE O 15 14 31 20 0 0 44804456 175140008 2800807 1240750 16986942 3466352 2354964 284705 66947169 180131815 29715699 3623255 0 0 10443144 11188563 0 0 467041 14312191 38983759 54471034 53795577 12476135 126336238 223870654 285156429 38432216 8671312 185438438 276485117 X THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY'S (PICI) MISSION IS TO DEVELOP AND ACCELERATE ACCESS TO BREAKTHROUGH CANCER THERAPIES, CURATING INNOVATION FROM DISCOVERY TO PATIENT ACCESS. false false 46776153 3623255 1240750 PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) ENCOURAGES ADVANCES IN CANCER IMMUNOTHERAPY RESEARCH, COLLABORATION, AND DISCOVERY, AND THE TRANSLATION OF THESE ADVANCES INTO CURES AND TREATMENTS FOR THE BENEFIT OF PATIENTS. TO DO THIS, PICI PARTNERS WITH ITS CONSORTIUM OF PREEMINENT HOSPITALS AND ACADEMIC RESEARCH CENTERS TO CONDUCT ITS DISCOVERY AND CLINICAL RESEARCH AND PROVIDES ITS PARTNERS WITH SHARED RESEARCH RESOURCES, SUCH AS SCIENTIFIC EQUIPMENT, CONSUMABLES, BIOINFORMATICS ANALYSIS, AND A SPECIMEN BIOBANK. PICI ALSO FUNDS AND OTHERWISE SUPPORTS CANCER IMMUNOTHERAPY RESEARCH WITHIN ITS CONSORTIUM. 46776153 true true false false false false false false false false true true true false true true true false false true true true false false true false false true false true false false false true false false false false false false false false true true true true false false true 32 0 true 31 true false false false false false false false false false false false false X 15 14 true false false false false true true true true false false true true true true true true true true false AL AK AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS NV NH NJ NM NY NC ND OH OK OR PA RI SC TN VA WA WV WI X SARA COBLIN 6288997600 1 LETTERMAN DRIVE SUITE D3500 SAN FRANCISCO CA 94129 X TARAK MODY CHIEF BUSINESS OFF. THRU 8/25 40.0 0.0 X 791771 0 94692 JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 40.0 0.0 X 703149 0 75026 KAREN E KNUDSEN COSTELLO CEO AS OF 03/2025 40.0 0.0 X X 655478 0 58978 KEVIN MARKS CHIEF LEGAL OFFICER 40.0 0.0 X 623269 0 75194 CHRIS CABANSKI THRU 1225 SR DIR, NETWORK CLIN. RESEARCH 40.0 0.0 X 314624 0 200315 SARA COBLIN SR VP FINANCE & ADMIN. 40.0 0.0 X 444632 0 51918 SHANE CORCORAN SENIOR VP, STRAT. OPS. & COMMS 40.0 0.0 X 441686 0 32245 MARKO SPASIC SR MEDICAL DIR, HEAD OF MED 40.0 0.0 X 398778 0 21808 CHRISTEN DIPETRILLO HEAD OF INTELLECTUAL PROPERTY 40.0 0.0 X 330222 0 74541 SEAN N PARKER CHAIR OF THE BOARD & DIRECTOR 5.0 5.0 X X 0 0 0 MICHAEL POLANSKY EXECUTIVE VP & DIRECTOR 5.0 5.0 X X 0 0 0 TOM VAN LOBEN SELS TREASURER & DIRECTOR 1.0 0.0 X X 0 0 0 JEFFREY A BLUESTONE PHD VICE CHAIR & DIRECTOR 1.0 0.0 X 0 0 0 TONY COLES MD DIRECTOR THRU 10/25 0.8 0.0 X 0 0 0 ERIC ESRAILIAN MD MPH DIRECTOR 1.0 0.0 X 0 0 0 SCOTT GOTTLIEB MD DIRECTOR 1.0 0.0 X 0 0 0 BEN HOROWITZ DIRECTOR 1.0 0.0 X 0 0 0 JEFF HUBER DIRECTOR 1.0 0.0 X 0 0 0 BOB HUGIN DIRECTOR 1.0 0.0 X 0 0 0 REED JOBS DIRECTOR 1.0 0.0 X 0 0 0 BOB NELSEN DIRECTOR 1.0 0.0 X 0 0 0 BRUCE PARKER PHD DIRECTOR 1.0 0.0 X 0 0 0 BOB PITTMAN DIRECTOR 1.0 0.0 X 0 0 0 RAMY IBRAHIM MD DIRECTOR THRU 10/25 0.8 0.0 X 0 0 0 MARGO GEORGIADIS DIRECTOR 1.0 0.0 X 0 0 0 SUSAN DAWSON SECRETARY 5.0 5.0 X 0 0 0 4703609 0 684717 27 false true false PATHEON UK LIMITED KINGFISHER DRIVE SWINDON 0 UK SN3 5BZ VACCINE MFG. 2586957 STANFORD UNIVERSITY 415 BROADWAY STREET REDWOOD CITY CA 94063 PATENT/CLINIC EXP. 1232482 REGENTS OF THE UNIV OF CALIFORNIA 1111 FRANKLIN STREET 11TH FLOOR OAKLAND CA 94607 CLINICAL TRIAL EXP. 999585 DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02215 PATENT/CLINIC EXP. 880244 REGENTS OF UNIV OF CAL SAN FRANC 1111 FRANKLIN STREET 11TH FLOOR OAKLAND CA 94607 PATENT & LICENSE EXP 656549 21 2491522 172648486 175140008 LICENSE FEES 900099 40750 40750 CONSULTING REV. 900099 1200000 1200000 1240750 3465310 3465310 0 284705 284705 0 0 0 1042 1042 1042 1042 0 2491522 0 0 0 0 0 0 0 0 0 180131815 1240750 3751057 3373255 3373255 0 250000 250000 0 2707897 1270723 1363703 73471 0 6961962 4492490 2272029 197443 133273 81614 48235 3424 971268 587619 375715 7934 414163 261120 145719 7324 0 3245104 3122456 122648 0 379762 0 379762 0 0 0 0 1477419 1147470 235838 94111 60914 567 59975 372 142690 76848 63850 1992 361615 267161 85718 8736 0 1617210 921810 663056 32344 804068 610010 185086 8972 0 3550707 3544219 4600 1888 0 0 0 165194 7223 157971 0 COLLABORATIVE RESEARCH PROG. 21015152 21015152 0 0 PATENT & LICENSE EXPENSE 4125033 4125033 0 0 INSTITUTION STAFF SUPPORT 1423770 1423770 0 0 RECRUITING 304324 0 304324 0 310797 197613 84154 29030 53795577 46776153 6552383 467041 682163 552055 27944828 37003694 0 0 1956768 26854850 713816 662829 0 0 400000 418530 0 0 2610092 2958586 7901030 7901030 295000 0 0 0 51705196 54432280 136078266 161974562 0 0 1484525 299043 223870654 285156429 7876148 8351742 0 0 0 0 0 0 0 0 0 0 0 0 0 0 30556068 319570 38432216 8671312 X 174101042 243998841 11337396 32486276 185438438 276485117 223870654 285156429 X 126336238 -8576420 -26713139 X false true X true false X MEMORIAL SLOAN KETTERING CANCER CENTER NEW YORK NY UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON TX UNIVERSITY OF CALIFORNIA LOS ANGELES LOS ANGELES CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO CA UNIVERSITY OF PENNSYLVANIA PHILADELPHIA PA DANA-FARBER CANCER INSTITUTE BOSTON MA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI NEW YORK NY FRED HUTCHINSON CANCER RESEARCH CENTER ST LOUIS MO WEILL CORNELL MEDICINE NEW YORK NY BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE DUARTE CA WASHINGTON UNIVERSITY IN ST LOUIS ST LOUIS MO CHILDREN'S HOSPITAL OF PHILADELPHIA PHILADELPHIA PA UNIVERSITY OF PITTSBURGH PITTSBURGH PA UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES CA STANFORD MEDICINE STANFORD CA UNIVERSITAT BASEL BASEL SZ MASSACHUSETTS GENERAL HOSPITAL BOSTON MA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 720271 720271 0 0 0 0 7180759 7180759 0 0 ARSENAL BIOSCIENCES 25001565 F 3T BIOSCINECES 1215654 F GEORGIAMUNE INC. 23423447 F APRICITY HEALTH, LLC 232280 F SENTI BIOSCIENCES, INC. 26000 F XAIRA THERAPEUTICS 4533334 F 54432280 IMAGINAB 1004281 F DISPATCH BIO 57245163 F MOONLIGHT BIO 15582384 F AKAMIS 626106 F LYELL IMMUNOPHARMA,INC 11211245 F TWAIN 5000000 F ARSENAL BIOSCIENCES 53619294 F 3T BIOSCIENCES 14376541 F KIIK THERAPEUTICS 3309548 F 161974562 0 LEASE LIABILITY 319570 319570 X 144842256 -8576420 -26713139 -35289559 180131815 180131815 53795577 53795577 53795577 PART X, LINE 2: THE ORGANIZATION, A CALIFORNIA NOT-FOR-PROFIT CORPORATION, IS EXEMPT FROM INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (IRC) AND SECTION 23701D OF THE CALIFORNIA REVENUE AND TAXATION CODE, EXCEPT TO THE EXTENT OF UNRELATED BUSINESS INCOME UNDER IRC SECTIONS 511 THROUGH 515. UNRELATED BUSINESS INCOME TAX, IF ANY, IS IMMATERIAL. AS OF DECEMBER 31, 2025 AND 2024, THE ORGANIZATION HAD NO UNCERTAIN TAX POSITIONS REQUIRING ACCRUAL. THE ORGANIZATION MAY BE SUBJECT TO ROUTINE AUDIT BY THE INTERNAL REVENUE SERVICE (IRS); HOWEVER, THERE ARE CURRENTLY NO AUDITS FOR ANY TAX PERIODS IN PROGRESS. THE ORGANIZATION HAS NO UNRECOGNIZED TAX BENEFITS OR LIABILITIES AS OF DECEMBER 31, 2025 AND 2024. Part XI, LINE 2D: INVESTMENT WRITE OFF $ (26,713,139) true Europe (Including Iceland and Greenland) 0 1 Program Services SERVICES&SPONSORSHIPS 15680 Europe (Including Iceland and Greenland) 0 0 Grantmaking 250000 East Asia and the Pacific 0 0 Program Services RESEARCH 88800 Europe (Including Iceland and Greenland) 0 1 Program Services VACCINE MANUFACTURING 2586957 Europe (Including Iceland and Greenland) 0 0 Investments 626106 East Asia and the Pacific 0 0 Investments 5000000 0 2 0 2 8567543 8567543 Europe (Including Iceland and Greenland) PROGRAM SUPPORT 250000 ACH TRANSFER 0 1 false false true false false false PART I, LINE 2 PICI AWARDS GRANTS SUBJECT TO A MASTER COLLABORATION AGREEMENT AND A SPECIFIC GRANT AGREEMENT SUBJECT TO EACH INSTITUTION. EACH INSTITUTION SUBMITS PROJECT PROPOSALS WHICH ARE EVALUATED TO ENSURE THEY ARE WITHIN THE CHARITABLE MISSION BEFORE APPROVAL. ALSO, EACH INSTITUTION AND GRANT RECIPIENT MUST PROVIDE PICI WITH ANNUAL REPORTS OF PROJECT PROGRESS AND ASSOCIATED SPEND. PART I, LINE 3, NUMBERS (5) AND (6) EACH OF THESE INVESTMENTS ARE PROGRAM-RELATED INVESTMENTS OF PICI. PICI INVESTS IN COMPANIES TO ACCELERATE FACILITATING THE DEVELOPMENT OF NOVEL CANCER THERAPIES. EACH INVESTMENT COMPANY MUST PROVIDE QUARTERLY FINANCIALS AND PICI IS REPRESENTED ON THE BOARD OF DIRECTORS FOR ONE OF THE INVESTMENTS. RESEARCH SPONSORSHIP WAS ALIGNED WITH THE COMPANY MISSION AND THE REMAINING IMMATERIAL SPEND WAS WITH VENDORS TO SUPPORT CLINICAL TRIALS AND EMPLOYEE DEVELOPMENT. PART I, LINE 3 ACCRUAL BASIS WSCOLLABORATIVE CONSULTING false PARTY 2491522 2491522 0 2491522 2491522 true CONQUER CANCER FOUNDATION 2318 MILL ROAD ALEXANDRIA VA 22314 311667995 501(C)(3) 1000000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 21115 042263040 501(C)(3) 178420 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE BOX 69 NEW YORK NY 10065 912154267 501(C)(3) 167500 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 820714 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY THE J DAVID GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501(C)(3) 175000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY REGENTS OF THE UNIVERSITY OF CALIFORNIA 10920 WILSHIRE BLVD LOS ANGELES CA 90024 956006143 GOVT 133886 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN 333 CALIFORNIA ST SAN FRANCISCO CA 94143 946036493 GOVT 191308 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET ROOM 310 PHILADELPHIA PA 19104 231352685 501(C)(3) 254161 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1400 PRESSLER STREET HOUSTON TX 77030 746001118 501(C)(3) 127267 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF PITTSBURGH 420 FIFTH AVENUE PITTSBURGH PA 15260 260965591 501(C)(3) 249999 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY WEILL CORNELL MEDICINE 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 75000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY 11 0 PART I, LINE 2: PICI AWARDS GRANTS SUBJECT TO A MAIN COLLABORATION AGREEMENT AND A SPECIFIC GRANT AGREEMENT SUBJECT TO EACH INSTITUTION. PICI AND EACH INSTITUTION JOINTLY REVIEW AND APPROVE PROJECT PROPOSALS TO ENSURE THEY HAVE A LEGITIMATE RESEARCH PURPOSE AND ARE WITHIN THE CHARITABLE MISSION BEFORE APPROVAL. ALSO, EACH INSTITUTION AND GRANT RECIPIENT MUST PROVIDE PICI WITH ANNUAL REPORTS OF PROJECT PROGRESS AND ASSOCIATED SPEND. X true true X X X X true false false false false false false true false JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 624119 0 0 0 79030 0 10500 0 64526 0 778175 0 0 0 KEVIN MARKS CHIEF LEGAL OFFICER 622099 0 0 0 1170 0 10500 0 64694 0 698463 0 0 0 SHANE CORCORAN SENIOR VP, STRAT. OPS. & COMMS 440516 0 0 0 1170 0 10500 0 21745 0 473931 0 0 0 TARAK MODY CHIEF BUSINESS OFF. THRU 8/25 391895 0 0 0 399876 0 30854 0 63838 886463 0 0 0 SARA COBLIN SR VP FINANCE & ADMIN. 443462 0 0 0 1170 0 10500 0 41418 0 496550 0 0 0 MARKO SPASIC SR MEDICAL DIR, HEAD OF MED 397608 0 0 0 1170 0 0 0 21808 0 420586 0 0 0 CHRISTEN DIPETRILLO HEAD OF INTELLECTUAL PROPERTY 329052 0 0 0 1170 0 9856 0 64685 0 404763 0 0 0 KAREN E KNUDSEN COSTELLO CEO AS OF 03/2025 604600 0 50000 0 878 0 10500 0 48478 0 714456 0 0 0 CHRIS CABANSKI THRU 1225 SR DIR, NETWORK CLIN. RESEARCH 313483 0 0 0 1141 0 155308 0 45007 0 514939 0 0 0 PART I, LINE 1A ANYONE TRAVELING OVER 3000 MILES CAN FLY BUSINESS CLASS OR FIRST CLASS (IF ONLY 2 LEVELS OF SERVICE ARE OFFERED). VP'S CAN TRAVEL BUSINESS OR FIRST CLASS FOR TRAVEL OVER 2000 MILES. PART I, LINE 3 THE ORGANIZATION FOLLOWS THE PROCESS SET FORTH IN ITS BYLAWS TO REVIEW AND APPROVE THE TOTAL COMPENSATION OF ITS CHIEF EXECUTIVE OFFICER, INCLUDING SALARY, BONUS, AND BENEFITS. THE BYLAWS REQUIRE THE BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE TO REVIEW ANY COMPENSATION PACKAGES, AND TO APPROVE SUCH COMPENSATION ONLY AFTER DETERMINING THAT THE COMPENSATION IS JUST AND REASONABLE. THIS REVIEW AND APPROVAL OCCURS WHEN THE CHIEF EXECUTIVE OFFICER IS HIRED, WHEN THE TERM OF EMPLOYMENT OF SUCH OFFICER IS RENEWED OR EXTENDED, AND WHEN THE COMPENSATION OF SUCH OFFICER IS MODIFIED, UNLESS THE MODIFICATION APPLIES TO SUBSTANTIALLY ALL OF THE EMPLOYEES OF THE ORGANIZATION. PART I, LINE 4A TARAK MODY RECEIVED A SEVERANCE IN THE AMOUNT OF $399,096. PART I, LINE 7 MOST OF PICI'S EMPLOYMENT AGREEMENTS, WHICH ARE NEGOTIATED AT ARMS-LENGTH WITH REFERENCE TO COMPARABILITY DATA, CONTAIN A PROVISION PERMITTING ANNUAL INCENTIVE BONUSES, WHICH ARE CAPPED AT UP TO A FIXED PERCENTAGE. JOHN CONNOLLY PHD EMPLOYEE HOME LOAN X 750000 662829 false true true 662829 FORM 990, PART I, LINE 1 DESCRIPTION OF ORGANIZATION MISSION: THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) IS A SAN FRANCISCO-BASED NONPROFIT WHICH HAS ESTABLISHED COLLABORATION BETWEEN THE COUNTRY'S LEADING IMMUNOTHERAPY RESEARCHERS AND CANCER CENTERS, INCLUDING STANFORD UNIVERSITY; THE UNIVERSITY OF CALIFORNIA, LOS ANGELES; THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO; THE UNIVERSITY OF PENNSYLVANIA; DANA FARBER CANCER INSTITUTE; AND GLADSTONE INSTITUTES. PICI ALSO SUPPORTS TOP RESEARCHERS AT OTHER INSTITUTIONS, INCLUDING CITY OF HOPE; FRED HUTCHINSON CANCER RESEARCH CENTER; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; INSTITUTE FOR SYSTEMS BIOLOGY; MEMORIAL SLOAN KETTERING CANCER CENTER; THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER; WEILL CORNELL MEDICAL COLLEGE; CHILDREN'S HOSPITAL OF PHILADELPHIA, UNIVERSITY OF PITTSBURGH, UNIVERSITY OF SOUTHERN CALIFORNIA (LA), UNIVERSITAT BASEL, MASSACHUSETTS GENERAL, AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS. BY FORGING ALLIANCES WITH ACADEMIC, INDUSTRY, AND NONPROFIT PARTNERS PICI SUPPORTS NOVEL RESEARCH TO FULFILL ITS MISSION: TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNE THERAPIES TO TRANSFORM ALL CANCERS INTO CURABLE DISEASES. FORM 990, PART VI, SECTION A, LINE 1 THE BOARD OF DIRECTORS IS COMPRISED OF ONE 'CLASS A' DIRECTOR WITH THE BALANCE OF THE DIRECTORS SERVING AS 'CLASS B' DIRECTORS. THE CLASS A DIRECTOR MUST BE PRESENT TO CONSTITUTE A QUORUM, UNLESS THE CLASS A DIRECTOR'S RECUSAL IS REQUIRED BY LAW OR CORPORATE POLICY. EACH DIRECTOR IS ENTITLED TO ONE VOTE. ANY ACT OF THE BOARD OF DIRECTORS REQUIRES THE AFFIRMATIVE VOTE OF BOTH THE CLASS A DIRECTOR AND A MAJORITY OF THE CLASS B DIRECTORS PRESENT AT A MEETING AT WHICH A QUORUM IS PRESENT, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS. PICI DOES HAVE AN EXECUTIVE COMMITTEE. IT HAS ALL THE AUTHORITY OF THE BOARD OF DIRECTORS BETWEEN REGULAR AND SPECIAL MEETINGS, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS OR BY THE BOARD OF DIRECTORS IN SPECIFIC INSTANCES. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO AND REVIEWED BY THE BOARD OF DIRECTORS AT ITS NEXT REGULARLY SCHEDULED MEETING. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS, KEY EMPLOYEES, AND OFFICERS HAVE A BUSINESS RELATIONSHIP AND/OR FAMILY RELATIONSHIP: JOHN CONNOLLY, SUSAN DAWSON, ERIC ESRAILIAN, SCOTT GOTTLIEB, BEN HOROWITZ, JEFF HUBER, REED JOBS, BOB NELSEN, BRUCE PARKER, SEAN PARKER, BOB PITTMAN, MICHAEL POLANSKY, TOM VAN LOBEN SELS, KAREN E. KNUDSEN (COSTELLO). FORM 990, PART VI, SECTION A, LINE 7A THE DESIGNATOR HAS THE AUTHORITY TO APPOINT MEMBERS OF PICI'S GOVERNING BODY. FORM 990, PART VI, SECTION A, LINE 7B THE DESIGNATOR HAS THE AUTHORITY TO REMOVE MEMBERS OF PICI'S GOVERNING BODY, TO CONSENT TO SUCH REMOVAL BY THE BOARD, AND TO CONSENT TO ANY AMENDMENTS TO PICI'S BYLAWS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE AUDIT COMMITTEE. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD AUTHORIZES AND OVERSEES A REVIEW OF THE ADMINISTRATION OF THE CONFLICT OF INTEREST POLICY. THE REVIEW CONSIDERS THE LEVEL OF COMPLIANCE WITH THE POLICY, THE CONTINUING SUITABILITY OF THE POLICY, AND WHETHER THE POLICY SHOULD BE MODIFIED AND IMPROVED. IF A TRANSACTION ARISES WHERE THERE IS A CONFLICT OF INTEREST, THE PERSON WITH SUCH CONFLICT IS NOT ALLOWED TO VOTE ON THE TRANSACTION NOR BE PRESENT FOR SUCH VOTE. THE CONFLICT OF INTEREST POLICY COVERS EACH DIRECTOR, CORPORATE OFFICER, TOP MANAGEMENT OFFICIAL, TOP FINANCIAL OFFICIAL AND EACH KEY EMPLOYEE OF PICI, AND OTHERS THAT PICI MAY IDENTIFY. FORM 990, PART VI, SECTION B, LINE 15A THE ORGANIZATION FOLLOWS THE PROCESS SET FORTH IN ITS BYLAWS TO REVIEW AND APPROVE THE TOTAL COMPENSATION OF ITS CHIEF EXECUTIVE OFFICER, INCLUDING SALARY, BONUS, AND BENEFITS. THE BYLAWS REQUIRE THE BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE TO REVIEW ANY COMPENSATION PACKAGES, AND TO APPROVE SUCH COMPENSATION ONLY AFTER DETERMINING THAT THE COMPENSATION IS JUST AND REASONABLE. THIS REVIEW AND APPROVAL OCCURS WHEN THE CHIEF EXECUTIVE OFFICER IS HIRED, WHEN THE TERM OF EMPLOYMENT OF SUCH OFFICER IS RENEWED OR EXTENDED, AND WHEN THE COMPENSATION OF SUCH OFFICER IS MODIFIED, UNLESS THE MODIFICATION APPLIES TO SUBSTANTIALLY ALL OF THE EMPLOYEES OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 15B THE ORGANIZATION DOES NOT COMPENSATE ITS CORPORATE OFFICERS, OTHER THAN ITS CEO, BUT ADHERES TO THE FOLLOWING PROCEDURES FOR ITS CEO AND KEY EMPLOYEES: THE BOARD OF DIRECTORS (OR DULY AUTHORIZED AND INDEPENDENT BOARD COMMITTEE) APPROVES THE SALARY OF PICI'S CEO AND KEY EMPLOYEES ONLY AFTER HAVING CONFIRMED IT IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATION ORGANIZATIONS. FORM 990, PART VI, SECTION C, LINE 19 PICI'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE AS REQUIRED BY LAW. FORM 990, PART XI, LINE 9: OTHER CHANGES IN NET ASSETS OR FUND BALANCES INVESTMENT WRITE OFF $(26,713,139) ----------- (26,713,139) MAVERIC LLC 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 853467441 COVID-19 CLIN CA 0 0 PICI SEAN N PARKER FOUNDATION 314 LYTTON AVE PALTO ALTO CA 94301 274389819 NONPROFIT SUP CA 501(C)(3) PF PICI true ECONOMIC INNOVATION GROUP INC 616 H STREET NW SUITE 550 WASHINGTON DC 20001 462450336 PUBLIC INTERE DC 501(C)(4) N/A PICI true PARATOPE INC 1 LETTERMAN DRIVE SUITE D3500 SAN FRANCISCO CA 94129 992858074 SOCIAL WELFAR CA 501(C)(4) N/A PICI true false false false false false false false false false false false false false false false false false true false SEAN N PARKER FOUNDATION R 29000000 BOOK VALUE PART I, IDENTIFICATION OF DISREGARDED ENTITIES: NAME OF DISREGARDED ENTITY: MAVERIC, LLC ADDRESS: 1 LETTERMAN DRIVE, D3500 SAN FRANCISCO, CA 94129 EIN: 85-3467441 PRIMARY ACTIVITY: COVID-19 CLINICAL TRIAL MANAGEMENT (CURRENTLY INACTIVE) DIRECT CONTROLLING ENTITY: PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY PART V, LINE 2 THE SEAN N. PARKER FOUNDATION MADE A RECOVERABLE GRANT IN 2021. THE RECOVERABLE GRANT WAS FULLY REPAID IN 2025. SCHEDULE R, SUPPLEMENTAL INFORMATION: THE CLASS A DIRECTOR ALSO HAS A CONTROLLING INTEREST IN SEVERAL PASSIVE INVESTMENT VEHICLES. THESE INVESTMENT VEHICLES AND THE TAX-EXEMPT ENTITIES DISCLOSED UNDER PART II ABOVE MAY TECHNICALLY BE CONSIDERED "RELATED ORGANIZATIONS" OF PICI FOR IRS FORM 990 REPORTING PURPOSES THROUGH THEIR RELATIONSHIP WITH THE CLASS A DIRECTOR. THE PASSIVE INVESTMENT VEHICLES HAVE NO TRANSACTIONS OR BUSINESS RELATIONSHIPS WITH PICI AND ARE NOT DISCLOSED ON SCHEDULE R.